ARTICLE | Company News

Chiron, Prosetta "no entry cost" HCV deal

June 22, 2004 7:00 AM UTC

CHIR granted a non-exclusive license to Prosetta (San Francisco, Calif.) to develop and commercialize therapeutics against certain HCV drug targets. The agreement is the first under which CHIR is offering access to its HCV technology with a "no entry cost" option. ...